TNYA insider trading
HealthcareTenaya Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Company website: www.tenayatherapeutics.com
TNYA insider activity at a glance
FilingIQ tracks 126 insider transactions for TNYA in filings since Aug 4, 2021. The most recent transaction is dated Sep 10, 2026.
Across the full history, 20 open-market purchases
and 76 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TNYA insider trades is 53.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TNYA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TNYA?
- FilingIQ tracks 126 Form 4 insider transactions for TNYA (Tenaya Therapeutics, Inc.), covering filings from Aug 4, 2021 onwards. 10 of those are dated within the last 90 days.
- Are TNYA insiders net buyers or net sellers?
- Across the full Form 4 history for TNYA, 20 transactions (16%) were open-market purchases and 76 (60%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TNYA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TNYA in?
- Tenaya Therapeutics, Inc. (TNYA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $133.80M.
Methodology & sources
Every TNYA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.